Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection
- PMID: 32630514
- PMCID: PMC7345920
- DOI: 10.3390/ph13060132
Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection
Erratum in
-
Correction: Palmeira et al. Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection. Pharmaceuticals 2020, 13, 132.Pharmaceuticals (Basel). 2024 Mar 25;17(4):411. doi: 10.3390/ph17040411. Pharmaceuticals (Basel). 2024. PMID: 38675502 Free PMC article.
Abstract
SARS-CoV-2 Spike protein was predicted by molecular docking to bind the host cell surface GRP78, which was suggested as a putative good molecular target to inhibit Covid-19. We aimed to confirm that GRP78 gene expression was increased in blood of SARS-CoV-2 (+) versus SARS-CoV-2 (-) pneumonia patients. In addition, we aimed to identify drugs that could be repurposed to inhibit GRP78, thus with potential anti-SARS-CoV-2 activity. Gene expression studies were performed in 10 SARS-CoV-2 (-) and 24 SARS-CoV-2 (+) pneumonia patients. A structure-based virtual screen was performed with 10,761 small molecules retrieved from DrugBank, using the GRP78 nucleotide binding domain and substrate binding domain as molecular targets. Results indicated that GRP78 mRNA levels were approximately four times higher in the blood of SARS-CoV-2 (+) versus SARS-CoV-2 (-) pneumonia patients, further suggesting that GRP78 might be a good molecular target to treat Covid-19. In addition, a total of 409 compounds were identified with potential as GRP78 inhibitors. In conclusion, we found preliminary evidence that further proposes GRP78 as a possible molecular target to treat Covid-19 and that many clinically approved drugs bind GRP78 as an off-target effect. We suggest that further work should be urgently carried out to confirm if GRP78 is indeed a good molecular target and if some of those drugs have potential to be repurposed for SARS-CoV-2 antiviral activity.
Keywords: Covid-19; GRP78; SARS-CoV-2; antiviral; gene expression; repurposed drugs; virtual screening.
Conflict of interest statement
The authors declare no conflict of interest. M.H.V. is member of the research team of a project financed by Celgene. M.H.V. is member of the team of a grant co-financed by AMGEN. These companies had no role in the decision to publish this manuscript, nor were they involved in the writing of this manuscript.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7345920/bin/pharmaceuticals-13-00132-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7345920/bin/pharmaceuticals-13-00132-g002.gif)
Similar articles
-
Identification of a druggable site on GRP78 at the GRP78-SARS-CoV-2 interface and virtual screening of compounds to disrupt that interface.J Comput Aided Mol Des. 2024 Jan 24;38(1):6. doi: 10.1007/s10822-023-00546-w. J Comput Aided Mol Des. 2024. PMID: 38263499
-
Current Strategies of Antiviral Drug Discovery for COVID-19.Front Mol Biosci. 2021 May 13;8:671263. doi: 10.3389/fmolb.2021.671263. eCollection 2021. Front Mol Biosci. 2021. PMID: 34055887 Free PMC article. Review.
-
The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection.J Biol Chem. 2021 Jan-Jun;296:100759. doi: 10.1016/j.jbc.2021.100759. Epub 2021 May 7. J Biol Chem. 2021. PMID: 33965375 Free PMC article.
-
Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.mBio. 2021 Mar 30;12(2):e03681-20. doi: 10.1128/mBio.03681-20. mBio. 2021. PMID: 33785634 Free PMC article.
-
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.Drug Resist Updat. 2020 Dec;53:100721. doi: 10.1016/j.drup.2020.100721. Epub 2020 Aug 26. Drug Resist Updat. 2020. PMID: 33132205 Free PMC article. Review.
Cited by
-
Correction: Palmeira et al. Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection. Pharmaceuticals 2020, 13, 132.Pharmaceuticals (Basel). 2024 Mar 25;17(4):411. doi: 10.3390/ph17040411. Pharmaceuticals (Basel). 2024. PMID: 38675502 Free PMC article.
-
SARS-CoV-2 spike protein induces endothelial inflammation via ACE2 independently of viral replication.Sci Rep. 2023 Aug 28;13(1):14086. doi: 10.1038/s41598-023-41115-3. Sci Rep. 2023. PMID: 37640791 Free PMC article.
-
New progresses on cell surface protein HSPA5/BiP/GRP78 in cancers and COVID-19.Front Immunol. 2023 May 18;14:1166680. doi: 10.3389/fimmu.2023.1166680. eCollection 2023. Front Immunol. 2023. PMID: 37275848 Free PMC article. Review.
-
Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-O-gallate (EGCG) in SARS-CoV-2 infection: Major interactions with host/virus proteases.Phytomed Plus. 2023 Feb;3(1):100402. doi: 10.1016/j.phyplu.2022.100402. Epub 2022 Dec 30. Phytomed Plus. 2023. PMID: 36597465 Free PMC article. Review.
-
GRP78, a Novel Host Factor for SARS-CoV-2: The Emerging Roles in COVID-19 Related to Metabolic Risk Factors.Biomedicines. 2022 Aug 17;10(8):1995. doi: 10.3390/biomedicines10081995. Biomedicines. 2022. PMID: 36009544 Free PMC article. Review.
References
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous